1. Airaksinen E, Wahlin A, Forsell Y, Larsson M. Low episodic memory performance as a premorbid marker of depression: evidence from a 3-year follow-up. Acta Psychiatr Scand 2007;115:458–65.
2. Bastos AG, Guimaraes LS, Trentini CM. Neurocognitive changes in depressed patients in psychodynamic psychotherapy, therapy with fluoxetine and combination therapy. J Affect Disord 2013;151:1066–75.
3. Betry C, Pehrson AL, Etievant A, Ebert B, et al. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonism. Int J Neuropsychopharmacol 2013;16:1115–27
4. Bora E, Harrison BJ, Yucel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med 2013;43:2017–26.
5. Bowie CR, Gupta M, Holshausen K, Jokic R, et al. Cognitive remediation for treatment-resistant depression: effects on cognition and functioning and the role of online homework. J Nerv Ment Dis 2013;201:680–5.
6. Burt DB, Zembar MJ, Niederehe G. Depression and memory impairment: a meta-analysis of the association, its pattern, and specificity. Psychol Bull 1995;117:285–305.
7. Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014;68:60–82.
8. Constant EL, Adam S, Gillain B, Seron X, et al. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depress Anxiety 2005;21:78–89.
9. Disner SG, Beevers CG, Haigh EA, Beck AT. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci 2011;12:467–77.
10. du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol 2014;24:160–71.
11. Elgamal S, McKinnon MC, Ramakrishnan K, Joffe RT, et al. Successful computer-assisted cognitive remediation therapy in patients with unipolar depression: a proof of principle study. Psychol Med 2007;37:1229–38.
12. Fava M, Iosifescu DV, Pedrelli P, Baer L. Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom 2009;78:91–7.
13. Fava M, Lophaven S, Olsen CK, Effects of vortioxetine on cognitive symptoms in major depressive disorder. 26th ECNP congress, Barcelona, Spain, 5–9 October 2013, Poster P.2.f.012.
14. Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 2003;18:9–14.
15. Goeldner C, Ballard TM, Knoflach F, Wichmann J, et al. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology 2013;64:337–46.
16. Greer TL, Sunderajan P, Grannemann BD, Kurian BT, et al. Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction? Depress Res Treat 2014;(2014):627863.
17. Guilloux JP, Mendez-David I, Pehrson A, Guiard BP, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology 2013;73:147–59.
18. Hammar A, Ardal G. Cognitive functioning in major depression – a summary. Front Hum Neurosci 2009;3:26.
19. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, Guardia-Olmos J, et al. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res 2009;43:855–63.
20. Herrera-Guzman I, Gudayol-Ferre E, Lira-Mandujano J, Herrera-Abarca J, et al. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Res 2008;160:72–82.
21. Hinkelmann K, Moritz S, Botzenhardt J, Muhtz C, et al. Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study. Psychoneuroendocrinology 2012;37:685–92.
22. Hinkelmann K, Moritz S, Botzenhardt J, Riedesel K, et al. Cognitive impairment in major depression: association with salivary cortisol. Biol Psychiatry 2009;66:879–85.
23 Jensen JB, du Jardin KG, Song D, Budac D, et al. Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. Eur Neuropsychopharmacol 2014;24:148–59.
24. Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat 2014;10:349–54.
25. Knegtering H, Eijck M, Huijsman A. Effects of antidepressants on cognitive functioning of elderly patients. A review. Drugs Aging 1994;5:192–9.
26. Lam RW, D S, Danchenko N, Rive B, et al. Psychometric development of Perceived Deficits Questionnaire – Depression (PDQ-D) in patients with Major Depressive Disorder. Slide presentation at the ISPOR 16th Annual European Conference, Dublin, Ireland, November 2–6, 2013.
27. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. J Affect Disord 2012;140:113–24.
28. Lezak, M. Neuropsychological Assessment. New York: Oxford University Press, 1995.
29. Lezak MD. Neuropsychological assessment. Oxford: Oxford University Press, 1995.
30. Li Y, Raaby KF, Sanchez C, Gulinello M. Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behav Brain Res 2013;256:520–8.
31. Mahableshwarkar AR ZJ, Jacobson W, Chen Y, Keefer RS. Efficacy of vortioxetine on cognitive function in adult patients with major depressive disorder: results of a randomized, double-blind, active-referenced, placebo-controlled trial. CINP Congress, Vancouver, 2014.
32. Majer M, Ising M, Kunzel H, Binder EB, et al. Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders. Psychol Med 2004;34:1453–63.
33. Mannie ZN, Barnes J, Bristow GC, Harmer CJ, et al. Memory impairment in young women at increased risk of depression: influence of cortisol and 5-HTT genotype. Psychol Med 2009;39:757–62.
34. Mathers C, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLOS Medicine 2006;3:e442.
35. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety 2013;30:515–27.
36. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17:1557–67.
37. Millan MJ, Agid Y, Brune M, Bullmore ET, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 2012;11:141–68.
38. Mork A, Montezinho LP, Miller S, Trippodi-Murphy C, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013 Apr;105:41–50.
39. Mork A, Pehrson A, Brennum LT, Nielsen SM, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012;340:666–75.
40. Moussavi S, Chatterji S, Verdes E, Tandon A, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:851.
41. Murray CJ, Vos T, Lozano R, Naghavi M, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197–223.
42. Naismith SL, Redoblado-Hodge MA, Lewis SJ, Scott EM, et al. Cognitive training in affective disorders improves memory: a preliminary study using the NEAR approach. J Affect Disord 2010;121:258–62.
43. Neu P, Bajbouj M, Schilling A, Godemann F, et al. Cognitive function over the treatment course of depression in middle-aged patients: correlation with brain MRI signal hyperintensities. J Psychiatr Res 2005;39:129–35.
44. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014;19:121–33.
45. Raskin J, Wiltse CG, Siegal A, Sheikh J, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900–9.
46. Reppermund S, Ising M, Lucae S, Zihl J. Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis. Psychol Med 2009;39:603–14.
47. Reppermund S, Zihl J, Lucae S, Horstmann S, et al. Persistent cognitive impairment in depression: The role of psychopathology and altered hypothalamic-pituitary-adrenocortical (HPA) system regulation. Biol Psychiatry 2007;62:400.
48. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med 2013 Oct 29:1–12.
49. Roiser JP, Sahakian BJ. Hot and cold cognition in depression. CNS Spectr 2013;18:139–49.
50. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacol Ther 2014 (in press).
51. Simons CJ, Jacobs N, Derom C, Thiery E, et al. Cognition as predictor of current and follow-up depressive symptoms in the general population. Acta Psychiatr Scand 2009; 120:45–52.
52. Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull 2013;139:81–132.
53. Thomas AJ, Gallagher P, Robinson LJ, Porter RJ, et al. A comparison of neurocognitive impairment in younger and older adults with major depression. Psychol Med 2009;39:725–33.
54. Trivedi MH, Greer TL. Cognitive dysfunction in unipolar depression: implications for treatment. J Affect Disord 2014;152–154:19–27.
55. Vos T, Flaxman AD, Naghavi M, Lozano R, et al. Years lived with disability (YLDs) for 1,160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163–96.
56. Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, et al. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry 2004;56:101–12.
57. Wagner S, Doering B, Helmreich I, Lieb K, et al. A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr Scand 2012;125:281–92.
58. Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry 2009;70:1588–97.
59. Wroolie TE, Williams KE, Keller J, Zappert LN, et al. Mood and neuropsychological changes in women with midlife depression treated with escitalopram. J Clin Psychopharmacol 2006;26:361–6.
60. Zajecka J, Kornstein SG, Blier P. Residual symptoms in major depressive disorder: prevalence, effects, and management. J Clin Psychiatry 2013;74:407–14.
61. Zobel AW, Schulze-Rauschenbach S, von Widdern OC, Metten M, et al. Improvement of working but not declarative memory is correlated with HPA normalization during antidepressant treatment. J Psychiatr Res 2004;38:377–83.
Prof. Dr. Christian Otte, Charité Universitätsmedizin Berlin, Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, E-Mail: firstname.lastname@example.org